Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Gynecologic 2Breast 2Sarcoma 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Osteoarthritis 1Cancer Pain 1Adenomatous Polyposis Coli 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Duration of Therapy × Gastrointestinal × Clear all
NCT00140894 2019-09-20

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 4 Terminated
62 enrolled
Gastrointestinal

Cancer Pain, Osteoarthritis, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡